Although mouse models of MS confirm the close involvement of monocytes in disease pathogenesis, clinical trials using CCR2 antagonists did not demonstrate efficacy (EU Clinical Trials: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000073-64). Here, CCR2 is linked to myeloid sarcoma.